Cargando…

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings

This analysis describes participants’ opioid use disorder (OUD) outcomes for 18 months after discontinuing extended-release buprenorphine injection (BUP-XR, SUBLOCADE). METHODS: The RECOVER (Remission From Chronic Opioid Use: Studying Environmental and Socioeconomic Factors on Recovery) study recrui...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyett, Brent, Nadipelli, Vijay R., Solem, Caitlyn T., Chilcoat, Howard, Bickel, Warren K., Ling, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022675/ https://www.ncbi.nlm.nih.gov/pubmed/36111991 http://dx.doi.org/10.1097/ADM.0000000000001070

Ejemplares similares

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study
por: Ling, Walter, et al.
Publicado: (2020)

Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study
por: Ling, Walter, et al.
Publicado: (2019)

Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study
por: Dhanda, Rahul, et al.
Publicado: (2019)

Posttrial Access to Medical Interventions: Intricacies, Challenges, and Solutions
por: Singh, Harmanjit, et al.
Publicado: (2019)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
por: Towers, Craig V., et al.
Publicado: (2020)

Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data
por: Leal, Jose, et al.
Publicado: (2013)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment
por: Ling, Walter, et al.
Publicado: (2019)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort Data
por: Bellows, Brandon K., et al.
Publicado: (2021)

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder
por: Ronquest, Naoko A, et al.
Publicado: (2018)

Benefits of using intrathecal buprenorphine
por: Rabiee, Seyed Mozaffar, et al.
Publicado: (2014)

Effectiveness of two extended-release buprenorphine formulations during postoperative period in neonatal rats
por: Zhang, Mingyun, et al.
Publicado: (2022)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Lipid bound extended release buprenorphine (high and low doses) and sustained release buprenorphine effectively attenuate post‐operative hypersensitivity in an incisional pain model in mice (Mus musculus)
por: Navarro, Kaela, et al.
Publicado: (2021)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended
por: Du, Xianglin L., et al.
Publicado: (2021)

Group Telegaming Through Immersive Virtual Reality to Improve Mental Health Among Adolescents With Physical Disabilities: Pre- and Posttrial Protocol
por: Lai, Byron, et al.
Publicado: (2022)

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product
por: Enomoto, Masataka, et al.
Publicado: (2017)

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route
por: Kharidia, Jahnavi, et al.
Publicado: (2021)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

Benefit-Risk Analysis of Buprenorphine for Pain Management
por: Hale, Martin, et al.
Publicado: (2021)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
por: Chappuy, Mathieu, et al.
Publicado: (2021)

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade(®)) for Opioid Use Disorder Fourteen Days after Administration
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets (Callithrix jacchus)
por: Fabian, Niora J., et al.
Publicado: (2023)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats
por: Cowan, Alan, et al.
Publicado: (2015)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
por: Cook, R. R., et al.
Publicado: (2023)

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
por: Marsden, John, et al.
Publicado: (2022)

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation
por: Lowry, Natalie, et al.
Publicado: (2022)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Postoperative respiratory depression in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine
por: Komatsu, Ryu, et al.
Publicado: (2022)

Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers
por: Duncan, Laura G., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jiaacigesjpdvummpre854c11o